查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1613107

伴同性诊断市场：按技术、适应症和最终用户划分 - 2025-2030 年全球预测

Companion Diagnostics Market by Technology (Immunohistochemistry, In Situ Hybridization, Next-Generation Sequencing), Indication (Cancer, Cardiovascular Diseases, Infectious Diseases), End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

据预测，2023年伴同性诊断市场价值为66.4亿美元，预计到2024年将达到73亿美元，复合年增长率为10.65%，到2030年将达到134.9亿美元。

精准医学的一个重要方面，伴同性诊断是实验室测试或测定，旨在透过识别指示治疗点反应的生物标记来确定特定治疗对患者的适用性和有效性。随着对个人化医疗的日益重视，对伴同性诊断的需求也在增加，以确保有针对性的治疗方法，实现有效的患者治疗效果，同时减少副作用。其应用范围广泛，在肿瘤学、免疫学和感染疾病领域尤为突出，量身定制的治疗可以显着改善患者的治疗效果。最终用户主要包括医院、诊断实验室和製药公司，它们依靠这些工具来增强治疗通讯协定并提高研究能力。市场开拓的驱动力包括技术创新、癌症发病率上升、政府推动精准医疗的倡议以及製药公司加大对药物诊断联合开发的投资。潜在的商机包括扩大这些诊断可发现的适应症范围、诊断公司和药品製造商之间的合作伙伴关係，以及医疗基础设施发达的新兴市场需求的增加。然而，也存在开发成本高、监管复杂性和报销系统有限等挑战，这些挑战可能会阻碍市场扩张和可及性。创新的关键领域是开发非侵入性液态切片测试以及整合人工智慧和机器学习来分析复杂资料以进行预测诊断。企业应专注于策略联盟和探索监管途径，以利用新机会，同时解决现有限制。了解市场特征至关重要。在快速的技术进步以及製药和诊断行业之间持续合作发展的需求的推动下，市场竞争激烈且充满活力。透过根据这些创新和挑战调整策略，公司可以有效地利用伴同性诊断在不断发展的精准医疗保健领域的成长潜力。

主要市场统计
基准年[2023] 66.4亿美元
预计年份 [2024] 73亿美元
预测年份 [2030] 134.9亿美元
复合年增长率（%） 10.65%

市场动态：揭示快速发展的伴同性诊断市场的关键市场洞察

供需的动态交互作用正在改变伴同性诊断市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 伴同性诊断在药物开发中的重要性日益增加
    • 对个人化药物和标靶治疗的需求不断增长
    • 活性化次世代定序仪创新研发
  • 市场限制因素
    • 开发和实施伴同性诊断的高成本
  • 市场机会
    • 诊断技术的持续技术进步
    • 鼓励伴同性诊断的开发和批准的有利监管政策
  • 市场挑战
    • 与伴同性诊断测试相关的报销问题

波特的五力：驾驭伴同性诊断市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解伴同性诊断市场的外部影响

外部宏观环境因素在塑造伴同性诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解伴同性诊断市场的竞争状况

对伴同性诊断市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵伴同性诊断市场供应商绩效评估

FPNV定位矩阵是评估伴同性诊断市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘伴同性诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对伴同性诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 伴同性诊断在药物开发中的重要性日益增加
      • 对个人化药物和标靶治疗的需求增加
      • 加强次世代定序创新的研究与开发
    • 抑制因素
      • 开发和实施伴同性诊断的高成本
    • 机会
      • 诊断技术的持续技术进步
      • 有利的监管政策促进伴同性诊断的开发和核准
    • 任务
      • 与伴同性诊断测试相关的报销问题
  • 市场区隔分析
    • 技术：次世代定序在精准医疗中受到欢迎
    • 最终用户：製药和生物製药行业的扩张推动了伴同性诊断的重要性
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章伴同性诊断市场：依技术分类

  • 免疫组织化学
  • 原位杂交
  • 次世代定序
  • 聚合酵素链锁反应

第七章按适应症分類的伴同性诊断市场

  • 癌症
    • 血癌
    • 乳癌
    • 大肠直肠癌
    • 肺癌
  • 心血管疾病
  • 感染疾病
  • 神经系统疾病

第八章伴同性诊断市场：依最终用户分类

  • 製药和生物製药公司
  • 参考实验室

第九章美洲伴同性诊断市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区伴同性诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲伴同性诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Thermo Fisher Scientific 与拜耳的创新合作为精准癌症治疗树立了新标准
    • 安捷伦与 Insight 结成策略联盟，加速伴同性诊断的发展
    • 开闢新的治疗视野：在 FoundationOne® CDx 诊断技术进步的支持下，FDA核准Capivasertib 和氟维司群联合治疗进行性乳癌
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Abnova Corporation
  • Agendia, Inc.
  • Agilent Technologies, Inc.
  • Almac Group
  • Amoy Diagnostics Co., Ltd.
  • ARUP Laboratories
  • Bio-Techne Corporation
  • Biogenex Laboratories, Inc
  • bioMerieux SA
  • Danaher Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Guardant Health, Inc
  • ICON PLC
  • Illumina, Inc.
  • Invivoscribe Technologies, Inc.
  • Myriad Genetics, Inc.
  • NG biotech
  • QIAGEN NV
  • R-Biopharm AG
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-433AB1DC2871

The Companion Diagnostics Market was valued at USD 6.64 billion in 2023, expected to reach USD 7.30 billion in 2024, and is projected to grow at a CAGR of 10.65%, to USD 13.49 billion by 2030.

Companion diagnostics, a vital aspect of precision medicine, refer to laboratory tests or assays designed to determine the suitability and effectiveness of a specific treatment for a patient by identifying biomarkers that indicate response to therapy. The need for companion diagnostics is growing owing to the increasing emphasis on personalized medicine, ensuring targeted therapeutics for efficient patient outcomes while reducing adverse effects. Their applications are expansive, prominently seen in oncology, immunology, and infectious diseases, where tailored treatments can significantly improve patient prognoses. End-user segments primarily include hospitals, diagnostic laboratories, and pharmaceutical companies, which utilize these tools for enhancing treatment protocols and research capabilities. Market growth is fueled by technological innovations, rising cancer prevalence, governmental initiatives promoting precision medicine, and expanding pharmaceutical investments in drug-diagnostic co-development. Potential opportunities include expanding indications discoverable by these diagnostics, partnerships between diagnostic firms and drug manufacturers, and increased demand in emerging markets with improving healthcare infrastructures. Nonetheless, challenges include high development costs, regulatory complexities, and limited reimbursement frameworks, which can hinder market expansion and accessibility. A critical area of innovation lies in the development of non-invasive liquid biopsy tests and integration of AI and machine learning to analyze complex data for predictive diagnostics. Companies should focus on strategic collaborations and regulatory pathway navigation to capitalize on emerging opportunities while addressing existing limitations. Understanding the nature of the market is crucial-it is highly competitive and dynamic, driven by rapid technological advancements and the continuous need for collaborative development between the pharmaceutical and diagnostic sectors. By aligning strategies with these innovations and challenges, businesses can effectively harness the growth potential of companion diagnostics in the evolving landscape of precision healthcare.

KEY MARKET STATISTICS
Base Year [2023] USD 6.64 billion
Estimated Year [2024] USD 7.30 billion
Forecast Year [2030] USD 13.49 billion
CAGR (%) 10.65%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Companion Diagnostics Market

The Companion Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing significance of companion diagnostics in drug development
    • Increasing demand for personalized medicines and targeted therapy
    • Rise in research and development for innovation in next generation sequencing
  • Market Restraints
    • High costs associated with development and implementation of companion diagnostics
  • Market Opportunities
    • Ongoing technological advancements in diagnostic techniques
    • Favorable regulatory policies encouraging the development and approval of companion diagnostics
  • Market Challenges
    • Reimbursement issues associated with companion diagnostic tests

Porter's Five Forces: A Strategic Tool for Navigating the Companion Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Companion Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Companion Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Companion Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Companion Diagnostics Market

A detailed market share analysis in the Companion Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Companion Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Companion Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Companion Diagnostics Market

A strategic analysis of the Companion Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Companion Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abnova Corporation, Agendia, Inc., Agilent Technologies, Inc., Almac Group, Amoy Diagnostics Co., Ltd., ARUP Laboratories, Bio-Techne Corporation, Biogenex Laboratories, Inc, bioMerieux SA, Danaher Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Guardant Health, Inc, ICON PLC, Illumina, Inc., Invivoscribe Technologies, Inc., Myriad Genetics, Inc., NG biotech, QIAGEN N.V., R-Biopharm AG, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Companion Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Immunohistochemistry, In Situ Hybridization, Next-Generation Sequencing, and Polymerase Chain Reaction.
  • Based on Indication, market is studied across Cancer, Cardiovascular Diseases, Infectious Diseases, and Neurological Disorders. The Cancer is further studied across Blood Cancer, Breast Cancer, Colorectal Cancer, and Lung Cancer.
  • Based on End-user, market is studied across Pharmaceutical & Biopharmaceutical Companies and Reference Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing significance of companion diagnostics in drug development
      • 5.1.1.2. Increasing demand for personalized medicines and targeted therapy
      • 5.1.1.3. Rise in research and development for innovation in next generation sequencing
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with development and implementation of companion diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing technological advancements in diagnostic techniques
      • 5.1.3.2. Favorable regulatory policies encouraging the development and approval of companion diagnostics
    • 5.1.4. Challenges
      • 5.1.4.1. Reimbursement issues associated with companion diagnostic tests
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Increasing preference of next-generation sequencing in precision medicine
    • 5.2.2. End-user: Expansion of pharmaceutical and biopharmaceutical sector driving the significance of companion diagnostics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Companion Diagnostics Market, by Technology

  • 6.1. Introduction
  • 6.2. Immunohistochemistry
  • 6.3. In Situ Hybridization
  • 6.4. Next-Generation Sequencing
  • 6.5. Polymerase Chain Reaction

7. Companion Diagnostics Market, by Indication

  • 7.1. Introduction
  • 7.2. Cancer
    • 7.2.1. Blood Cancer
    • 7.2.2. Breast Cancer
    • 7.2.3. Colorectal Cancer
    • 7.2.4. Lung Cancer
  • 7.3. Cardiovascular Diseases
  • 7.4. Infectious Diseases
  • 7.5. Neurological Disorders

8. Companion Diagnostics Market, by End-user

  • 8.1. Introduction
  • 8.2. Pharmaceutical & Biopharmaceutical Companies
  • 8.3. Reference Laboratories

9. Americas Companion Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Companion Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Companion Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Innovative Partnership Between Thermo Fisher Scientific and Bayer Sets New Standard in Precision Cancer Care
    • 12.3.2. Strategic Partnership between Agilent and Incyte Elevates Companion Diagnostic Development
    • 12.3.3. Unlocking New Treatment Horizons: FDA Approves Capivasertib & Fulvestrant Combo for Advanced Breast Cancer, Backed by FoundationOne(R) CDx Diagnostic Advances
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Abnova Corporation
  • 3. Agendia, Inc.
  • 4. Agilent Technologies, Inc.
  • 5. Almac Group
  • 6. Amoy Diagnostics Co., Ltd.
  • 7. ARUP Laboratories
  • 8. Bio-Techne Corporation
  • 9. Biogenex Laboratories, Inc
  • 10. bioMerieux SA
  • 11. Danaher Corporation
  • 12. Eli Lilly and Company
  • 13. F. Hoffmann-La Roche AG
  • 14. Guardant Health, Inc
  • 15. ICON PLC
  • 16. Illumina, Inc.
  • 17. Invivoscribe Technologies, Inc.
  • 18. Myriad Genetics, Inc.
  • 19. NG biotech
  • 20. QIAGEN N.V.
  • 21. R-Biopharm AG
  • 22. Siemens AG
  • 23. Sysmex Corporation
  • 24. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. COMPANION DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. COMPANION DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. COMPANION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COMPANION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COMPANION DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. COMPANION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023